Abstract: The present invention relates to a method for treating a Leber congenital amaurosis in a patient harbouring the mutation c.2991+1655 A>G in the CEP290 gene, comprising the step of administering to said patient at least one antisense oligonucleotide complementary to nucleic acid sequence that is necessary for preventing splicing of the cryptic exon inserted into the mutant c.
Type:
Application
Filed:
August 31, 2017
Publication date:
January 18, 2018
Applicants:
INSERM (Institut National de la Sante et de la Rec herche Medicale), CNRS (Centre National de la Recherche Scientifique ), GENETHON, UNIVERSITE PARIS DESCARTES, ENSCP - Chimie ParisTech - Ecole Nationale Superie ure de Chimie de Paris, Universite d'Evry-Val-d'Essonne, ASSISTANCE PUBLIQUE HOPITAUX DE PARIS
Inventors:
Jean-Michel ROZET, Antoine KICHLER, Isabelle PERRAULT, Josseline KAPLAN, Xavier GERARD, Daniel SCHERMAN, M. Arnold MUNNICH
Abstract: The present invention relates to an aqueous solution for organ preservation, in particular for the myocardium, the solution comprising: 100 mM to 130 mM of Na+; 12 mM to 15 mM of K+; 0.25 mM to 1.3 mM of Ca++; 0.5 ?M to 1.5 ?M of cyclosporin A; and 0.5 ?M to 1.5 ?M of taxol, and it also relates to the joint use of cyclosporin A and taxol in a solution for in vitro preservation of an organ, in particular the myocardium.
Type:
Application
Filed:
November 13, 2014
Publication date:
October 13, 2016
Applicants:
UNIVERSITE CLAUDE BERNARD LYON I, INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA REC HERCHE MEDICALE)
Abstract: The method of characterizing an ultrasound lesion (T) in organic tissues, the lesion being made by applying high intensity focused ultrasound delivered by a probe having its emission surface presenting a shape that is toroidal, consists in: after a period of at least two days from the end of ultrasound application, acquiring at least one characterization image (Ic) of the organic tissues; detecting the presence of a contrast border (16) in the characterization image (Ic); and from the contrast border (16), determining the extent of the ultrasound lesion.
Type:
Application
Filed:
October 7, 2014
Publication date:
August 4, 2016
Applicants:
EDAP TMS FRANCE, INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA REC HERCHE MEDICALE)
Inventors:
David MELODELIMA, Jeremy VINCENOT, Emmanuel BLANC
Abstract: The invention relates to methods for detecting inactivation of the DNA Homologous Recombination pathway in a patient, and in particular for detecting BRCA1 inactivation.
Type:
Application
Filed:
June 6, 2013
Publication date:
May 21, 2015
Applicant:
INSERM (Institut National de la Sante et de la Rec herche)
Abstract: The present invention relates to a transgenic animal mode system based on the development of transgenic mice bearing components of the human immune system. Specifically, the Invention relates to a Flk2 deficient Rag ā?cā transgenic mouse and the engraftment of said mouse with human hematopoietic stem cells. The present invention further presides methods for increasing the numbers of functionally competent human dendritic cells is and the hematopoietic targets cells that they interact with in said transgenic mouse through the administration of Flk2L. The transgenic animal model system of the invention may be used for testing human vaccine candidates, for screening potential Immune adjuvants and for developing novel therapeutics.
Type:
Application
Filed:
April 2, 2010
Publication date:
April 19, 2012
Applicants:
INSTITUT PASTEUR, INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA REC HERCHE)
Abstract: The present invention relates to the use of Neutrophil Gelatinase-Associated Lipocalin (NGAL) and/or SERPINA3 as biomarkers of the Mineralocorticoid Receptor (MR) activation in a patient. More particularly, the present invention relates to a method for predicting the responsiveness of a patient to a treatment with a MR antagonist or an aldosterone synthase inhibitor, said method comprising determining in a biological sample obtained from said patient the expression level of the NGAL gene and/or of the SERPINA3 gene.
Type:
Application
Filed:
October 21, 2009
Publication date:
October 20, 2011
Applicant:
INSERM (Institut National de la Sante et de la Rec herche Medicale)
Abstract: The present invention relates to inhibitors of progastrin induced repression of ICAT for treating and/or preventing colorectal cancer, adenomatous polyposis or metastasis displaying progastrin-secreting cells and cells in which the beta-catenin/Tcf-4-mediated transcriptional pathway is constitutively active.
Type:
Application
Filed:
May 21, 2007
Publication date:
August 19, 2010
Applicants:
INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA REC HERCHE MEDICALE), CENTRE NATIONAL DE LA RECHERECHE SCIENTIFIQUE- CNRS, UNIVERSITE DE MONTPELLIER 1